Alex Lockhart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex Lockhart has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Alina M. Hamilton
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
11 shared publications - Andrea Walens
Duke University
11 shared publications - Charles M. Perou
University of North Carolina at Chapel Hill 1 Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
11 shared publications - Cyrus Vaziri
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA
11 shared publications - Erin L. Kirk
University of North Carolina at Chapel Hill 10 Chapel Hill, North Carolina
11 shared publications - Gaorav P. Gupta
Lineberger Comprehensive Cancer Center
11 shared publications
Latest Publications
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Background:Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied.Methods:To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes.Results: Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78).Conclusions:HRD is associated with poor prognosis and enriched in the tumors of black women.Impact:RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Background:Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied.Methods:To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes.Results: Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78).Conclusions:HRD is associated with poor prognosis and enriched in the tumors of black women.Impact:RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Background:Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied.Methods:To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes.Results: Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78).Conclusions:HRD is associated with poor prognosis and enriched in the tumors of black women.Impact:RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Background:Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied.Methods:To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes.Results: Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78).Conclusions:HRD is associated with poor prognosis and enriched in the tumors of black women.Impact:RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- Open Access
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
- 23 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
Supplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer